Selcaxen (Selpercatinib) Capsules

Indicated for the treatment of patients with RET-positive tumors:

• 🔹 Non-Small Cell Lung Cancer (NSCLC): Metastatic RET fusion-positive NSCLC in adults.
• 🔹 Thyroid Cancer: Advanced or metastatic RET-mutant medullary thyroid cancer (MTC) or RET fusion-positive thyroid cancer in adults and pediatric patients (12 years and older).

Packaging: 40 mg capsules.

⚠️ ADMINISTRATION PROTOCOL (Weight-based):

• Dosing: Based on body weight:
  — Less than 50 kg: 120 mg twice daily.
  — 50 kg or greater: 160 mg twice daily.
• Frequency: Take orally twice daily, approximately 12 hours apart.
• Administration: Swallow whole. Do not crush or chew. Can be taken with or without food.
• Interaction: Avoid taking with proton pump inhibitors (PPIs) simultaneously if possible (follow doctor's instructions).

• Hypersensitivity to Selpercatinib.
• Pregnancy and breastfeeding (embryo-fetal toxicity).
• Severe hepatic impairment (requires dose modification).

Common adverse reactions include:

• 🩸 Labs: Increased AST/ALT (liver enzymes), hyperglycemia, decreased leukocytes.
• 📉 Cardiovascular: Hypertension, QT interval prolongation.
• 🌀 Physical: Dry mouth, diarrhea, fatigue, edema (swelling).
• Patients require regular monitoring of liver function and blood pressure.